Sun highlights OTC as it completes Ranbaxy deal

25 March 2015 - Deborah Wilkes

Archived

"An attractive opportunity" is how India's Sun Pharma describes the consumer healthcare business gained as part of its US$4.0 billion acquisition of Ranbaxy Laboratories from Japan's Daiichi Sankyo.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: